课题基金 / 基金详情

项目摘要

项目成果

David Sulzer的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(由申请人提供):帕金森病(PD)是最常见的运动障碍。在过去的15年里,在越来越多的基因中发现了致病突变,加快了我们对疾病机制的理解。与遗传发现相关的细胞生物学和免疫学过程的同时发现正在迅速提供对导致这种疾病的过程的见解。这就产生了一系列令人兴奋的挑战和机遇,需要通过讨论和交流意见加以解决。 据我们所知,从来没有一个基础研究会议专门讨论PD,这次会议将汇集具有不同科学背景的研究人员,他们对产生PD及其相关疾病的细胞机制感兴趣。首届PD GRC会议将于2015年6月28日至7月3日在科尔比索耶学院举行,并打算每两年举行一次。会议的具体内容将随着我们对PD的理解的发展而发展:第一次会议将特别讨论可能导致疾病及其伴随的神经元死亡的致病步骤。长期目标将是创造一种手段来分享关于帕金森病和相关疾病的病因和治疗的想法和数据,具体的集中领域将随着新的科学见解而改变。本次会议将汇集具有不同知识,观点和技术方法的科学家,将为数百万PD和相关疾病(包括路易体疾病和其他运动障碍)患者开发新的治疗方法。 本次成立大会的报名人数预计为178人,这是科尔比索耶学院的上限。美国国立卫生研究院被要求帮助支付48名早期职业研究人员的注册费用。这些研究人员将从受邀演讲者和那些有杰出海报摘要的人中选出。如果会议被与会者、戈登会议管理部门和NIH认为是成功的,它可以每两年继续和扩大一次。 我们设计了一种高度互动的形式,促进对前沿未发表结果的讨论,并支持对该领域的争议和需求进行有意义的对话。久经考验的GRC格式为学生,博士后研究员和教师创造了一个独特的机会,无论专业地位如何,都可以进行互动,并更深入地了解该领域或PD和运动障碍面临的基本问题,并建立可能导致突破的跨领域合作。我们还打算促进参与者的多样性,让妇女、少数民族和来自各种背景的科学家,包括在学术和商业机构工作的科学家出席和参与。
英文摘要
 DESCRIPTION (provided by applicant): Parkinson's disease (PD) is the most common motor disorder. Over the past fifteen years, the discovery of disease-causing mutations in a growing number of genes has accelerated the pace of our understanding of disease mechanisms. Simultaneous discoveries in cell biology and immunological processes related to the genetic discoveries are rapidly providing insights into the processes that lead to this disease. This creates an exciting series of challenges and opportunities to be addressed by the discussion and exchange of ideas. There has, to our knowledge, never been a basic research conference devoted to PD, and this conference will bring together investigators with diverse scientific backgrounds who share an interest in cellular mechanisms that produce PD and its related disorders. The inaugural PD GRC meeting will be held June 28-July 3, 2015 at Colby Sawyer College and is intended to recur biennially. The specific content of the Conference will evolve as our understanding of PD evolves: the first conference will in particular address pathogenic steps that may underlie the disease and its accompanying neuronal death. The long-term objective will be to create a means to share ideas and data on the cause and treatment of Parkinson's disease and related disorders, and the specific areas of concentration will change with new scientific insights. This meeting, by bringing together scientists with different knowledge, opinions, and technical approaches, will serve to develop new therapies for millions of patients of PD and related disorders including Lewy body diseases and other movement disorders. The enrollment for this inaugural meeting is expected to be 178, the limit at Colby Sawyer College. The NIH is being asked to help cover the registration costs for 48 early career investigators. These investigators will be chosen from the invited speakers and those with outstanding poster abstracts. If the meeting is deemed successful by attendees, the Gordon Conference administration, and the NIH, it can be continued and expanded on a biennial basis. We have designed a highly interactive format that fosters discussion of cutting-edge unpublished results and supports meaningful dialog of controversies and needs in the field. The well-tested GRC format creates a unique opportunity for students, post-doctoral fellows and faculty to interact regardless of professional status and gain a deeper understanding of fundamental questions facing the field or PD and movement disorders and to build cross-cutting collaborations that could lead to breakthroughs. We further intend to promote participant diversity by providing attendance and participation by women, minorities, and scientists from a variety of backgrounds, including those that work at academic and commercial institutions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dopamine 2020
Effects of Cannabis on Neuronal Translation
ROLES FOR ALPHA-SYNUCLEIN DEGRADATION AND CYTOSOLIC DOPAMINE IN PD PATHOGENESIS
Spectra-Physics Mai Tai HP Laser
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: